IceCure Medical Showcases ProSense® Success at Japanese Conference

Icecure Medical ( (ICCM) ) has issued an announcement.

IceCure Medical announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society Conference in July 2025, showcasing the ProSense® system’s effectiveness in breast cancer treatment. The conference highlighted positive clinical data, including a 99% recurrence-free rate with cryoablation, and awarded the Best of Breast Cancer award to an independent study demonstrating zero local recurrence. This positions IceCure for potential regulatory approval and commercial adoption in Japan, enhancing its market presence.

The most recent analyst rating on (ICCM) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s stock score is primarily affected by its challenging financial performance, with ongoing losses and cash flow issues. While there are positive signals from the recent earnings call, such as FDA progress and regional sales growth, these are outweighed by the company’s weak valuation and neutral technical indicators. Significant operational improvements are needed to enhance financial stability and investor confidence.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical is a company that develops and markets advanced cryoablation therapy systems using liquid nitrogen for tumor destruction. Their primary focus areas include breast, kidney, bone, and lung cancer. The company’s flagship product, the ProSense® system, offers a minimally invasive alternative to surgical tumor removal and is marketed globally.

Average Trading Volume: 316,762

Technical Sentiment Signal: Sell

Current Market Cap: $67.66M

Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.